“ALSTDF has conducted a very valuable program to screen candidate ALS drugs in ALS mice. At its best, this sort of program achieves two important goals: it tests for compounds that may prove therapeutic in ALS patients and it also probes the biology of ALS as a disease process. Both activities are an essential component of winning the battle against ALS.”

ROBERT H. BROWN, JR., M.D., D.PHIL.
Director of the Day Neuromuscular Research Laboratory and Muscular Dystrophy Association clinic at the Massachusetts General Hospital and Professor of Neurology, Harvard Medical School
Dear Friends and Family of ALSTDF:

Six years ago I beat my younger and larger brother Stephen arm wrestling – for the first time in ten years. This was his first symptom and a year and a half later Stephen was diagnosed with ALS.

Today my brother would physically remind you of Stephen Hawking. He uses a computer to talk and drives his wheelchair with buttons mounted on the headrest. He is 34 years old and unable to feed or care for himself. Why haven’t we cured this disease?

Our current scientific system has generated amazing advances in science and continuously generates novel ideas and new knowledge. This process has created our entire existing body of scientific literature. However, I am not sure that having an army of independently motivated scientists – scientists that do small scale projects selected by committee review, projects without coordination or follow up – is the best way to cure a disease like ALS. The quest for a way that strategically addresses the lack of treatments Stephen and all ALS patients face led to the formation of ALSTDF in April of 1999. As our fledgling R&D team began to strategize about the most effective way to treat ALS, we were greeted by a fertile ground of advances made by world-class researchers, while simultaneously discovering an enormous information and development gap. It was as if the government and charities of the world had planted orchard after orchard brimming with scientific discoveries and not bothered to harvest the fruit.

We do it differently. At ALSTDF, we began to collect all of the information. Trials, animal studies, drugs in development, biomarkers, theories, opportunities – and four years later, ALSTDF is now an integrated team of professional scientists and drug development experts working each day through emerging data to strategically advance the most promising ideas to patients.

We operate our laboratory like a factory. Instead of solely focusing on one potential therapy, we research multiple pathways of halting the disease and concurrently test as many plausible avenues as our facilities and funds allow. What this means is that we scan all literature and collaborate with leaders in a variety of fields to generate targets for drugs and therapies. We use this information to select and then test drugs in our laboratory on a mouse model of ALS. And our approach is working – as you can see in this annual report, we have made significant strides toward treatments for ALS and are moving forward drugs discovered in our lab into the clinics.

Envision a new future. Envision a future where strategic plans to effectively treat disease and improve human health are built and implemented without regard to profit or publication. Where we mine the vast scientific knowledge we have compiled and build large-scale programs to deliver tangible improvements in human health. It’s not about not require new science or technology. It’s about good strategic planning, effective use and investigation of existing knowledge, and execution at a scale that can succeed.

Thank you for helping us build the Foundation that is working to build that future for Stephen and all people affected with ALS. The accomplishments of this year belong to you our supporters and the patients we work for. Help us finish the task and continue to harvest the orchard of scientific ideas until we slow, arrest, and cure ALS.

Thank you.

James Allen Heywood, d’Arbeloff  Founding Director

Research & Development (R&D) Highlights 2002

Advanced the first potential new treatment discovered in ALSTDF’s internal R&D program towards clinical study in ALS patients (ritonavir, a drug already marketed for HIV/AIDS).

Increased the scale of drug testing in our mouse model of ALS and our approach is working – as you can see in this annual report, we have made significant strides toward treatments for ALS and are moving forward drugs discovered in our laboratory on a mouse model of ALS. And our approach is working – as you can see in this annual report, we have made significant strides toward treatments for ALS.

Envision a new future. Envision a future where strategic plans to effectively treat disease and improve human health are built and implemented without regard to profit or publication. Where we mine the vast scientific knowledge we have compiled and build large-scale programs to deliver tangible improvements in human health. It’s not about not require new science or technology. It’s about good strategic planning, effective use and investigation of existing knowledge, and execution at a scale that can succeed.

Thank you for helping us build the Foundation that is working to build that future for Stephen and all people affected with ALS. The accomplishments of this year belong to you our supporters and the patients we work for. Help us finish the task and continue to harvest the orchard of scientific ideas until we slow, arrest, and cure ALS.

Thank you.

James Allen Heywood, d’Arbeloff  Founding Director

Patient Services Highlights 2002

Held four ALS 101 seminars to provide patients, caretakers, and physicians with information on new research and treatments for ALS.

Responded directly to more than 3,000 inquiries from ALS patients, families, and friends. Wrote, printed, and distributed three research newsletters to a circulation of more than 10,000 patients, families, physicians and researchers.

Investigated controversial, experimental therapies for ALS, providing objective answers to patients’ questions on these untried therapeutics and their proponents.

see page 9 for more...

Advancement Highlights 2002

Raised more than $4.3 million for ALS research, a 7% increase over 2001.

Doubled revenue of the Family and Friends Community (FFC) to $1.8 million.

Enabled 68 FFC fundraising initiatives on behalf of ALSTDF to raise money in support of ALSTDF’s drug discovery program.

Successfully obtained grant funding to sponsor the first clinical trial arising from ALSTDF’s screening program.

Provided grants to outside researchers as well as funding the ALSTDF laboratory.

see page 7 for more...

ABOUT ALS

Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a fatal neurological disorder that causes muscle atrophy, paralysis, and respiratory failure. ALS has no prejudice – it occurs worldwide, with no age, ethnic, or economic boundaries. 30,000 Americans have ALS today. Up to 8,000 new cases are diagnosed in the U.S. each year; 10% of patients die within 5 years of diagnosis. There is no known treatment or cure.

A non-profit biotechnology company dedicated to developing effective treatments for today’s ALS patients. ALSTDF combines the passion and dedication of a nonprofit organization with the entrepreneurial and scientific spirit of a biotechnology company. ALSTDF runs the leading drug discovery program focused on ALS and combines in-house technology and expertise with key scientific collaborations to accelerate the process of finding effective treatments for ALS.
Accelerating Drug Discovery For ALS

During 2002, ALSTDF’s Research & Development team made many significant strides forward in its quest for an ALS treatment and cure. Several expansions of existing systems and programs allowed us to pursue a greater number of targets in ALS, and to test more drugs aimed at those targets. In addition, key staff additions and the appointment of a Clinical Advisory Board have increased ALSTDF’s effectiveness, visibility, and recognition as leaders in drug discovery for ALS.

Exploring Multiple and New Targets for ALS

Data from both internal and external research efforts continue to lead ALSTDF towards pursuit of a broad range of promising drug targets across important ALS disease pathways. These pathways include inflammation, apoptosis, protein misfolding, excitotoxicity, cell replacement, and more recently, proteasome dysfunction and cell cycle regulation. Cell cycle targets are of particular interest since they may represent more “upstream” disease pathways leading to the activation of “downstream” pathways such as changes in basal cell metabolism, inflammatory/immune activation, glial proliferation, and apoptosis. This novel class of targets has yielded new drug leads, some of which have potential for clinical development.

Electronic Research Pipeline System

ALSTDF established a comprehensive data mining and information management process to evaluate its growing pool of drug targets (currently 50) and lead compounds (more than 400 in our pipeline). Of these lead compounds, 28 were selected for in vivo drug screening in our facility in 2002, and a total of more than 60 screening studies were completed.

External Research Program

Our External Research program was established to better inform our understanding of the ALS disease process and to help us select new and better targets for drug intervention. This outreach program initiated nearly 30 collaborations in 2002 with both academic and industry researchers inside and outside of the ALS field to acquire compounds for drug screening and to initiate targeted experiments that fill key gaps in the body of ALS knowledge.

Clinical Advisory Board

In 2002, ALSTDF appointed a Clinical Advisory Board comprised of leading researchers in ALS. The establishment of a Clinical Advisory Board was a critical step in ALSTDF achieving its mission to develop effective treatments for people living with ALS. Experts in researching, diagnosing and treating ALS, the group will partner with ALSTDF to develop effective treatments for people living with ALS. We are better positioned than ever to deliver against our time-critical mission.”

CHRISTOPHER PAZOLE, Ph.D.
Chief Operating Officer, Head of R&D

Chris joined ALSTDF in 2002, bringing 21 years of experience in the pharmaceutical and biotechnology industries to ALSTDF. He most recently was Vice President of Research for Phytex, Inc., a drug discovery and development biotech company, where he built and led a multidisciplinary and multinational research team and helped forge a variety of corporate alliances and partnerships. Before Phytelex, Chris held a series of positions in Pfizer’s Central Research Division, including management roles in the areas of neuroscience and inflammation discovery. At Pfizer, he was also involved in numerous pre-clinical and clinical development programs, ultimately serving as Director, Exploratory Development Planning before leaving Pfizer to join the biotech industry. Chris holds a Ph.D. from the University of Notre Dame in microbiology and biochemistry and spent five years as a post-doc at the National Institutes of Health in Bethesda, MD.

Chris led the R&D team through a number of improvements and refinements to the research pipeline and drug discovery processes that enabled ALSTDF to: more effectively manage the 400-plus drug leads considered for testing in the lab; secure a newly appointed Clinical Advisory Board; and move a drug candidate toward clinical trial.
Discovering Effective Treatments for People Living with ALS

**IN OUR LAB**

ALSTDF runs the largest drug screening program in a mouse model of ALS. In 2002, the number of mice housed and compounds screened in the SOD1 mouse model increased with the availability of more space in our new facility. Six drug screening studies were initiated each month, each involving 40 to 50 mice. As a result, there were approximately 1,000 mice in our facility and more than 20 drug studies ongoing at any one time.

**State-of-the-Art Laboratory Facilities & New Staff**

In 2002, ALSTDF relocated and expanded its drug screening program, the ALS Hope Drug Discovery Center, to a state-of-the-art laboratory and animal space located in the Partners Healthcare Building in Cambridge, MA. The new space enabled us to house more than 1,000 mice in an SPF animal facility run by Harvard. Harvard provided all facilities management and animal care support, as well as use of the procedure rooms in the facility suitable for all surgical procedures. In addition to the animal facility, we have dedicated laboratory space that holds all of our equipment for drug formulation, pharmacokinetic analysis, hematology, clinical chemistry, necropsy, histochemistry, and molecular biology. This year, ALSTDF has expanded the scientific expertise of their research team by adding two scientific leaders from the biotechnology industry. Our laboratory team now consists of a Director of Pharmacology, Laboratory Manager, eight Research Technicians and a Formulation Scientist. This team has all the necessary experience and expertise to effectively carry out drug evaluation studies in the SOD1 mouse model.

**Our First Clinical Drug Candidate**

In 2002, the first drug from ALSTDF’s screening program to be advanced towards clinical study in ALS patients was identified – ritonavir (a protease inhibitor currently marketed to treat HIV/AIDS). Additionally, a grant was secured to cover the majority of the cost of this study. Ritonavir was chosen for study in our mouse model of ALS because its reported pharmacological actions overlap with several ALS disease pathway targets. In this model, ritonavir produced modest but statistically significant slowing of disease symptom progression and extended lifespan. It has the potential to produce larger effects in humans. It also displayed serious side effects in the mice, requiring researchers to work out a delicate balance of toxicity and efficacy before deciding to advance ritonavir towards the clinic. Its side effects in humans are well-characterized and can also be quite serious. For this reason, the initial clinical trial of ritonavir in ALS patients (scheduled to start in late 2003) will focus on evaluating its safety profile, with sufficient disease assessments to detect any trends towards efficacy.

**PATIENTS TODAY**

**Treatment Information Reports**

ALSTDF maintains its commitment to patients by acting as a source of coherent information that empowers patients to partner with their physicians regarding their treatment. In 2002, our first full-time staff Treatment Coordinator answered more than 2,000 individual requests for information. Significant updates and improvements to www.als.net added in-depth information on drugs under evaluation, screening studies, and the status of certain lead compounds.

**“These refinements to screening should ensure that every drug is tested at a safe dose, and that each study is designed to generate the most reliable and accurate results.”**

**PHIL LAMBERT, Ph.D.**

**Director of Pharmacology**

Phil is a neuroscientist with 14 years of experience in research and drug discovery. He has worked on novel approaches to treating diseases of the neural and endocrine systems at both large pharmaceutical companies and in the biotech industry. Before joining ALSTDF, he was Director of Pharmacology for Waratah Pharmaceuticals, a start-up biotech company developing an islet regeneration therapy to treat type I diabetes. Phil led a group responsible for both the in-house and external drug development studies, which successfully drove the therapy into clinical trials. Before Waratah Phil held several positions in the Neural and Endocrine Biology Group at Regeneron Pharmaceuticals. Phil holds a Ph.D. in pharmacology from the University of London, England and spent 4 years in academia at Emory University Medical School in Atlanta, GA. Under Phil’s guidance, ALSTDF’s laboratory made a number of improvements to the screening process that will allow more cost-effective testing of potential treatments. These changes included a full-scale statistical analysis of the mouse colony used in the screening and a program called “pilot screening” – brief, 7-day studies pre-testing the selected dose of each drug to identify potential toxicity problems.
Accessing targeted drugs for testing in our mouse model of ALS. To date, we have successfully obtained donations of costly (or even impossible to purchase) drugs from more than 25 companies. In total, the market value of these drugs is nearly $2 million.

Forging sponsored research partnerships to test company’s promising drugs and to improve our drug testing technologies. Such partnerships represent a new revenue source for the Foundation.

Foundations

In 2002, ALSTDF raised nearly $1 million thanks to the generosity of several foundations (see p.12). A number of these gifts, including those from the California-based Larry L. Hillblom Foundation and the St. Louis-based Jack Orchard ALS Foundation, focused directly on specific research projects, while others, including another significant grant from an anonymous foundation as well as gifts from ALS Hope – the Chris Hobler/Jean Maritz ALS Foundation, provided much-needed financial support at a crucial time. We aim to cast our net even wider in the coming year, seeking support from foundations nationwide and increasing the number of grants in 2003.

Leadership Circles

As a member of one of the Leadership Circles, you demonstrate your leadership through annual gifts of $1,000 or greater. You provide support for ALSTDF’s laboratory operations, patient services, and clinical research into potential treatments for ALS. Thank you to all members of our Leadership Circles who continue to enable ALSTDF to make significant strides toward slowing, arresting, and curing ALS.

Donors

Founders’ Circle

$100,000-plus annually or $1 million or more cumulative giving
- ALS Hope
- Anonymous
- Alex and Birt d’Arbeloff
- Fran Delany Fund
- The Beatrice P. Delany Charitable Trust
- The Larry L. Hillblom Foundation
- George & Daphne Foundation
- The Jack Orchard ALS Foundation
- Edward Scott

Governors’ Circle

$25,000-plus annually
- Jim & Susan Amy ALS Fund
- Connecticut Friends For ALS Research
- Dreyfoos Indemnity Company
- Jennifer Furr
- Tom Lisan
- William and Maryleather
- Anthony Tucher

Directors’ Circle

$10,000-plus annually
- Addict A. and Valerica Leo Foundation
- ALS Family Charitable Foundation
- Galanter & Susanne Aron
- Bear, Stearns & Co., Inc.
- Ralph H. Shriver
- Boston Bruins
- Jen & Jennifer Currie
- Doug Douglas Effort
- Company Computer Corporation
- David Green Effort
- Marlene Hess
- Will Hubben ALS Research
- Jewish Community Fund
- Nancy & Jeffrey Hals
- Philanthropy Fund
- Gall Kendal
- Larry Linsky
- Betty Luken
- Mike Mcavit
- Mark McPike
- Matchbook Technologies, Inc.
- Former Standard Electronics
- Jim Doolan Effort
- Mark Reed B
- Ray For Le
- David Smol
- John & Eda Sobic
- John & Eda Sobic
- John & Eda Sobic
- Jim & Susan Amy ALS Fund
- Connecticut Friends For ALS Research
- Dreyfoos Indemnity Company
- Jennifer Furr
- Tom Lisan
- William and Maryleather
- Anthony Tucher

Associates’ Circle

$5,000-plus annually
- Abram’s Capital
- Brian & Mark Allen Fund
- Alan Lendenmann Co LLC
- Brian & Partners, Inc.
- Regina Loo
- Doug Duran Effort
- Me Family Foundation
- Bill Powers Effort
- Gall Kendal
- Larry Linsky
- Betty Luken
- Mike Mcavit
- Mark McPike
- Matchbook Technologies, Inc.
- Former Standard Electronics
- Jim Doolan Effort
- Mark Reed B
- Ray For Le
- David Smol
- John & Eda Sobic
- John & Eda Sobic
- John & Eda Sobic
- Jim & Susan Amy ALS Fund
- Connecticut Friends For ALS Research
- Dreyfoos Indemnity Company
- Jennifer Furr
- Tom Lisan
- William and Maryleather
- Anthony Tucher

There are an awful lot of groups to support in the health industry,” says Brit. “But when you something like this that is obviously different, it’s exciting.”

BRIT D’ARBELLOFF
In 2002, ALSTDF's Family and Friends Community (FFC) doubled their income from 2001, bringing in a total of $1.8 million. This was made possible through several additions to the FFC program, including an increase from one to three full-time support staff with fundraising and event-planning experience. FFC also provided families with new and expanded resources to assist them in their fundraising endeavors, including a Family and Friends Community Tool Kit that helped new members understand what was involved and get their efforts started. In addition, the new FFC website was created as a place for community partners to create their own web pages to tell their personal story and to create a fundraising and awareness tool to send to their network of family and friends.

Visit: www.alscommunity.org

Mary Lou Krauseneck Fund

In June of 2000, my aunt Mary Lou was given the diagnosis of ALS. Her prognosis offered her no hope and she was told nothing could be done. Shortly thereafter we discovered ALSTDF and its commitment to patients living with ALS today. We recognized increased funding would enable them to get equipment they needed, to hire top researchers and scientists, and to purchase SOD1 mice for drug studies.

Our family then had virtually no fundraising experience. Our first project was a cookbook put together by close family and friends. A few years later we have been joined by a dedicated, passionate group of men and women that put together by close family and friends. A few years later we have been joined by a dedicated, passionate group of men and women that are working to find a cure. We have raised $1.8 million in 2002. Thank you to each and every person that made the following efforts possible, and exhibited ALSTDF's values of Courage and Love.

**ALSTDF Board of Directors**

**ALSTDF's Family and Friends Community (FFC)**

FFC doubled their income from 2001, bringing in a total of $1.8 million. This was made possible through several additions to the FFC program, including an increase from one to three full-time support staff with fundraising and event-planning experience. FFC also provided families with new and expanded resources to assist them in their fundraising endeavors, including a Family and Friends Community Tool Kit that helped new members understand what was involved and get their efforts started. In addition, the new FFC website was created as a place for community partners to create their own web pages to tell their personal story and to create a fundraising and awareness tool to send to their network of family and friends.
ALSTDF is grateful to the many employers who generously match the gifts we receive from their employees.

**Matching Gifts**

Many employers offer matching gifts programs to support charitable organizations. To participate, you can either ask your employer for a matching gift program brochure or go directly to the employer’s website to find out if they have a matching gift policy. Matching gifts are typically sent to ALSTDF through the company’s Human Resources or Corporate Giving departments. Some employers require you to complete a form, while others have an online system. It’s important to check the requirements specified by your employer.

**Matching Gifts for Donors**

To participate in a matching gift program, you need to follow the steps outlined by your employer for completing a matching gift form. Here’s a general guide on how to proceed:

1. **Identify the Employer**
   - Check if your employer is listed in the donor’s guide or search online for matching gift programs.

2. **Locate the Form**
   - Ask your employer for a matching gift form or visit their corporate website.

3. **Complete the Form**
   - Fill in the required information, which usually includes your name, employer name, and gift amount.

4. **Submit the Form**
   - Submit the form to your employer’s Human Resources or Corporate Giving department, or through an online portal if available.

5. **Verify the Contribution**
   - After submitting the form, verify with your employer that the matching gift has been credited to your ALSTDF donation.

**Matching Gifts FAQs**

- **What is a matching gift program?**
  - A matching gift program is an employer-sponsored program that matches charitable contributions made by employees.

- **Who qualifies for a matching gift?**
  - Most employees are eligible, but it varies by company. Check with your employer for specific details.

- **How much does a matching gift program match?**
  - Matching gift programs can match 100% of your donation, up to a specific dollar amount, or a percentage of your donation. Check with your employer for details.

- **Can I match a donation made to ALSTDF?**
  - Yes, most companies allow matching gifts to charities like ALSTDF. Check with your employer to confirm.

- **Is it easy to participate?**
  - Participating in a matching gift program is straightforward. Follow the steps provided by your employer.

**Why Participate in a Matching Gift Program?**

- **Increase Donor Support**
  - Matching gifts can increase donor support by encouraging employees to choose ALSTDF.

- **Expand Your Reach**
  - By participating in a matching gift program, you can reach a broader audience that includes employees of participating companies.

- **Increase Your Impact**
  - Matching gifts can help you achieve your fundraising goals by increasing the total amount of money you receive.

**Tips for Participating**

- **Start Early**
  - Begin the process early to ensure your matching gift is credited to your ALSTDF donation.

- **Follow Up**
  - Follow up with your employer to ensure your matching gift form is received and processed.

- **Be Prepared**
  - Have all the necessary information ready, such as your employer’s name, address, and matching gift form.

Participating in a matching gift program can have a significant impact on ALSTDF’s fundraising efforts. By reaching out to your employer, you can help increase the number of donors and the total amount of money we receive. Thank you for considering participating in a matching gift program.
Memorials

ALSTDF acknowledges the following individuals who received gifts in memory during 2002. Our staff extends our deepest sympathy to their families and friends who continue to fight ALS even after their loved ones’ deaths.

Edward Abramson
John Alges
Henvetta Red Allen
Bryan Allan
Dirk Angermann
Theresa Barori
Steve Beaice
John T. Beatty
William Benes
James Benjamin
Andrea Benoit, MD
Al Berman
Robert Blanchard
Donald Blairs
Chris Bomsa
Joseph W. Brady
Marion Brady
George Brewood
Benjamin Brewer
Philip J. Brown
Harry Brown
James Brown
Monte Bryner
Julian E. Buchanan
Andi Busday
Patrick Burnett
Laurie Cassella
Beverly Sichel
Joan Schwartz
Giovanni Rizzacasa
Christine Rich
Kathy Rees
Craig Peffer
Dorothy Burke Odierna
Edward Myers, Sr.
John Scannell
John Joseph & Lynne Esselstein
Jeffrey Jones
Joli Day Spa
John Hancock Financial
Jewish Communal Fund
JEM Electronics, Inc.
James Murray Insurance
Martin & Marjory Jaffe
Jack Martin Insurance Group
Larry & Mary Isaacs
Insurance Institute for Highway Safety
Alan G. Inglis & Sally Scripture
J. Alan Inglis
Vincent J. Indorato Jr.
Russell Hughey
Greg & Christine Henk
Nicholas & Corelis Haliby
Carl Haefling
Betsy Leitch
Mark & Brenda Gordon
Evagelos Kavouriadis & Rudzewicz
John Rudzewicz
Edward & Martha Rosenthal
Stan & Bobbi Rice
Regina Rear
Ernie & Margaret Prisbe
J. Brian & Catherine Potts
Larry Plutnicki
James Perry
Christopher Pazoles
John & Patricia Pasquinelli
Maryann Parker
S. O’Sullivan UFG
Patrick & Nancy O’Connor
John O. & Elizabeth O’Connor
S. Stowell UGARIC
Gary & Rita Ostruz
Virginia Palacios
Maryann Parker
Joseph D. & Penelope Patschak
David & Patricia McMillan
Karen Loud
Gerard LoPorto
Jack & Marion Longwell
William Locker
Sarah Locklear
Charlie & Nancy Moncrief
Alyssa Lloyd
Nancy Lloyd
Lamp, O’Dell, Bartram, Levy & L&S Food Sales Corp.
Colleen Morrison
Rick Morgan
William Meehan
G. West Saltonstall
The Ryan Agency
Jill & Rosemary Salen
David & Patricia McMillan
Martin & Minnie Salen
Don Salen
Maryanne Salen
Beverly Salen
Annie Salen
Ronald Salen
Jared Salen
Nancy Vasey
Craig & Doni Val
Joe Valenti
Valerie Tyler
Mark & Terry Vanderven
Bob & Wendy VanderMolen
Julie Viscardi
David & Larry Voss
Kathleen Weisman
addGroup
Wenden & Anne Wener
Victor & Sally Werger
Shepherd Investment & Financial Advisory
Richard, Jr. & S. Werner
Amy Wiggins
George & Betty Whitley
Robert Winear
Women Giving Women
Wyland International Kanele, Inc.
Cara & Brenda Yngvesson
Mr. & Mrs. Zabala
Daniel Zabala
M. Zarakos UGARIC
Daniel Zaffe
mcmn.com

Special Vendors

ALSTDF thanks the following companies and people for enabling us to spend more dollars on drug discovery and less on operational costs through offering reduced rates and continued support.

- Bobby Usseren
- Cymal
- Corporate Limelite, Inc.
- Greg Gayna
- Hamilton Hughes Design
- Jackson Laboratories
- Interaction Institute
- Stacy Usseren
- CPR’s Printing
- Richard Howard
- Photography
- United Lithograph